Annovis Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANVS research report →
Range $21 – $30
Price Chart
About the company
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
- CEO
- Maria L. Maccecchini
- IPO
- 2020
- Employees
- 7
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on ANVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.36M
- P/E
- -0.46
- Fwd P/E
- 0.55
- PEG
- 0.03
- P/S
- 0.00
- P/B
- -2.41
- EV/EBITDA
- -0.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -8312.82%
- ROIC
- 7763.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,695,258
- Net Income
- $-28,854,197-17.3%
- EPS
- $-1.40+30.7%
- OCF Growth
- -17.0%
- FCF Growth
- -17.0%
- 52W High
- $5.50
- 52W Low
- $0.62
- 50D MA
- $1.06
- 200D MA
- $1.78
- Beta
- 1.35
- RSI (14)
- 39
- Avg Volume
- 1.81M
No earnings-call transcripts are available for ANVS yet.
- Free Float
- 88.2%
- Shares Outstanding
- 42.68M
- Float Shares
- 37.65M
of shares held by institutions
69 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Empery Asset Management, LP | 2.40M | ▲ 2.40M |
| Marshall Wace, Llp | 1.70M | ▼ 141.10K |
| Vanguard Capital Management LLC | 1.58M | ▼ 65.63K |
| Tudor Investment Corp Et Al | 1.36M | ▲ 1.36M |
| Vanguard Group Inc | 923.20K | ▲ 185.20K |
| Renaissance Technologies LLC | 736.03K | ▼ 266.17K |
| Two Sigma Investments, LP | 579.57K | ▼ 48.09K |
| Geode Capital Management, LLC | 324.42K | ▲ 40.60K |
| Blackrock, Inc. | 245.10K | ▼ 4.76K |
| Citadel Advisors LLC | 243.68K | ▲ 243.68K |
| Vanguard Fiduciary Trust Co | 224.24K | ▲ 46.71K |
| Morgan Stanley | 199.35K | ▲ 199.01K |
Held by 25 ETFs
Biggest fund positions in ANVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Hoffman Michael B | buy | 5,000,000 |
| Nov 6, 26 | Hoffman Michael B | buy | 5,000,000 |
| May 20, 26 | Hoffman Michael B | buy | 54,933 |
| May 20, 26 | Hoffman Michael B | buy | 18,849 |
| May 20, 26 | Hoffman Michael B | buy | 2,562 |
| Apr 2, 26 | Hoffman Michael B | buy | 713,800 |
| Dec 8, 25 | Hoffman Michael B | buy | 15,000 |
| Dec 8, 25 | Hoffman Michael B | buy | 30,000 |
| Nov 24, 25 | Hoffman Michael B | buy | 28,096 |
| Nov 24, 25 | Hoffman Michael B | buy | 415 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANVS coverage
Recent articles, reports, and earnings notes.
No research on ANVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANVS report →Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer's and Parkinson's Data Ahead of Buntanetap NDA
globenewswire.com · Nov 20
Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
globenewswire.com · Nov 17
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 13
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
globenewswire.com · Nov 12
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
globenewswire.com · Nov 9
Annovis Announces Pricing of $21.0 Million Public Offering
globenewswire.com · Nov 5
Annovis Announces Launch of Proposed Public Offering
globenewswire.com · Nov 4
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
globenewswire.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.